通讯员 雅沁 朱超 轶强 （来源：衢州日报） 转自：衢州日报 持续加码的研发投入，转化为实实在在的创新成果。2025年5月15日，旺林公司成立生物基黑色功能性 产品研究院，携手浙江科技大学、浙江农林大学、北京中医药大学等高校组建专业研发团队，按产品领 域细分研究方向，重点开展生物基黑色功能型产品的技术攻关与应用研究，尤其注重挖掘本地道地药材 资源，推动传统中药实现现代化转化。截至目前，公司已累计申请专利71项，其中发明专利28项、实用 新型专利17项，成功获得12项发明专利和17项实用新型专利；同时主导或参与制定多项国际、国家及行 业标准，以过硬技术优势牢牢站稳市场。 在深耕研发的同时，旺林公司稳步拓展业务边界、丰富产品矩阵，不断提升抗风险能力。"单一产品抗 风险能力弱，我们既要守住主业根基，也要主动拓展新赛道。"汪芳介绍，2025年6月，公司完成经营范 围变更，新增饲料添加剂生产、保健食品（预包装）销售等业务，进一步拓宽发展路径；同步重点布局 品牌建设，成功申请68项商标，持续提升品牌辨识度和影响力。"2025年，我们加大线上渠道布局力 度，积极参与各类行业展会，线上线下协同发力，全力拓宽销售路径、对接更多 ...

Core Viewpoint - Biobased products are considered "carbon neutral" and are essential for addressing climate change by replacing fossil-based products, especially in the context of dwindling petrochemical resources and global warming [1][5]. Market Overview - The global biobased products market is projected to grow from $22.8 billion in 2020 to $42.1 billion in 2024, with China leading the market at $19.9 billion, accounting for 47.27% of the global share [5][6]. - By 2025, the global market is expected to reach $48.1 billion, with China's share increasing to $23.1 billion, or 48.02% [5][6]. - The market is anticipated to exceed $80 billion within the next five years [5]. Industry Definition and Classification - Biobased products are defined as products derived from biomass (including plants, animals, and microorganisms) or biological processes (such as fermentation) [2]. - They can be categorized into two main types: biobased energy (solid, liquid, and gas forms) and biobased materials (macromolecular and small molecular biochemicals) [2][3]. Industry Chain - The biobased products industry chain includes upstream raw materials (crops, plant waste, and biomass), midstream processing companies that convert these materials into biobased products, and downstream applications in various sectors such as packaging, textiles, and transportation [6][7]. Policy Environment - The Chinese government has implemented various policies to promote the development of biobased products, emphasizing the reduction of fossil resource dependency and the promotion of a green economy [8][9]. Competitive Landscape - The biobased products industry in China is characterized by a diverse and tiered competitive landscape, with key players including Fengbei Bio, Kaisa Bio, Jindan Technology, and Wanhua Chemical [10][11]. - Notable companies like Anhui Huaheng Bio and Shanghai Kaisa Bio have established themselves as leaders in the biobased product sector, focusing on research, production, and sales of biobased materials [11][12]. Development Directions - The increasing global energy demand and the finite nature of conventional energy resources highlight the significance of biobased products as a sustainable alternative [13][14]. - The industry is seen as a crucial pathway towards achieving carbon neutrality, with ongoing technological advancements and cost reductions enhancing market prospects [15].

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. is pursuing an IPO in Hong Kong, revealing significant changes in key financial metrics, including a decline in gross margin from 40.4% in 2023 to 24.8% in 2024 and a drop in net margin from 23.0% to 8.5% [1] Business Model - The company focuses on bio-based products, utilizing biomanufacturing technology to produce amino acids, vitamins, and other bio-based products, which are widely used in various industries [2] - Amino acid products are the primary revenue source, accounting for 69.3% to 82.2% of total revenue from 2022 to the first half of 2025 [2] Financial Performance - Revenue growth is notable, increasing from 1.419 billion to 2.178 billion yuan from 2022 to 2024, with a compound annual growth rate of 23.9% [3] - The net profit decreased from 319 million yuan in 2022 to 185 million yuan in 2024, with a decline in the first half of 2025 compared to the same period in 2024 [4] - Gross margin has been declining, from 38.7% in 2022 to 24.8% in 2024, with further decline in the first half of 2025 [5] - Net margin has also significantly decreased from 22.5% in 2022 to 8.5% in 2024 [6] Revenue Composition - The revenue composition shows a decreasing trend in the share of amino acid products, while the share of vitamin products has fluctuated, and other bio-based products have seen an increase [8] Related Transactions - There is an overlap between major customers and suppliers, which raises concerns about the fairness of pricing and potential risks of interest transfer [9] Financial Challenges - Market price fluctuations and rising costs are significant challenges, with sales costs increasing by 41.7% in 2024 compared to 2023 [10][11] - The company faces risks related to research and development, including high uncertainty and potential delays in product launches [12] Competitive Landscape - The company holds a competitive advantage through technological leadership and a diversified product portfolio, but it faces intense competition that could impact its market share and profitability [13][14] Customer and Supplier Dynamics - Customer concentration remains stable, with major customers accounting for 9.0% to 15.4% of revenue, while supplier concentration is relatively low [15][16] Management and Governance - The company has a concentrated ownership structure, which may influence decision-making and potentially affect minority shareholders [16] - The management team has extensive experience in the biomanufacturing sector, which supports business development and strategic decision-making [18]